Ximeprox Tablet 200 mg contains Cefpodoxime Proxetil, a third-generation oral cephalosporin antibiotic with broad-spectrum activity against a wide range of Gram-positive and Gram-negative bacteria. It is commonly prescribed for the treatment of respiratory tract infections, urinary tract infections, skin infections, and certain sexually transmitted infections. Due to its good stability against beta-lactamase enzymes, Ximeprox Tablet 200 mg remains effective against many resistant bacterial strains.
Ximeprox is often initiated before the exact causative organism is identified, making it a reliable option for empirical therapy in susceptible infections.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Third Generation Cephalosporins
Ximeprox Tablet 200 mg is indicated for the treatment of infections caused by susceptible microorganisms, including:
Acute otitis media caused by Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis (including beta-lactamase-producing strains)
Pharyngitis and tonsillitis caused by Streptococcus pyogenes
Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis
Community-acquired pneumonia caused by Streptococcus pneumoniae or Haemophilus influenzae (including beta-lactamase-producing strains)
Acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (non-beta-lactamase-producing strains only), or Moraxella catarrhalis
Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes
Uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Staphylococcus saprophyticus
Uncomplicated gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains)
Rectal gonococcal infections in women caused by Neisseria gonorrhoeae
Ximeprox Tablet 200 mg is an oral third-generation cephalosporin with excellent resistance to beta-lactamase enzymes. Cefpodoxime Proxetil is a prodrug that is converted in the body to its active metabolite, cefpodoxime, after absorption from the gastrointestinal tract. Cefpodoxime exerts bactericidal activity by inhibiting bacterial cell wall synthesis.
Approximately 29–33% of the active drug is excreted unchanged in the urine within 12 hours, making renal function an important consideration during dosing.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins
Leads to weakening and rupture of the bacterial cell wall
Results in bacterial cell death
Active against a wide range of Gram-positive and Gram-negative organisms
Adults and Adolescents (13 years and older):
Pharyngitis/tonsillitis: 100 mg every 12 hours for 5–10 days
Acute maxillary sinusitis: 200 mg every 12 hours for 10 days
Community-acquired pneumonia: 200 mg every 12 hours for 14 days
Acute bacterial exacerbation of chronic bronchitis: 200 mg every 12 hours for 10 days
Skin and skin structure infections: 400 mg every 12 hours for 7–14 days
Uncomplicated urinary tract infections: 100 mg every 12 hours for 7 days
Uncomplicated gonorrhea: Single dose of 200 mg
Rectal gonococcal infections in women: Single dose of 200 mg
Infants and Pediatric Patients (2 months to 12 years):
Acute otitis media: 5 mg/kg body weight every 12 hours for 5 days
Pharyngitis/tonsillitis: 5 mg/kg body weight every 12 hours for 5–10 days
Acute maxillary sinusitis: 5 mg/kg body weight every 12 hours for 10 days
High doses of antacids or H2-receptor blockers may reduce absorption of cefpodoxime
Probenecid may inhibit renal excretion and increase plasma levels of cefpodoxime
Ximeprox Tablet 200 mg is contraindicated in patients with:
Known hypersensitivity or allergy to cephalosporin antibiotics
Cefpodoxime is generally well tolerated. Possible side effects include:
Diarrhea
Nausea and vomiting
Abdominal pain
Skin rash, urticaria, or itching
Cefpodoxime is classified as US FDA Pregnancy Category B. It should be used during pregnancy only if clearly needed. Cefpodoxime is excreted in human breast milk, therefore caution is advised when administered to nursing mothers.
Dose adjustment is required in patients with renal impairment
Use with caution in patients receiving potent diuretics
Prolonged use may lead to overgrowth of non-susceptible organisms
In patients with severe renal impairment (creatinine clearance <30 ml/min), dosing intervals should be extended to 24 hours
No dosage adjustment is required in hepatic impairment
Store in a dry place away from light and heat. Keep out of the reach of children.
Login Or Registerto submit your questions to seller
No none asked to seller yet